Brii Biosciences Reports Major Developments and 2025 Financial Results Brii Biosciences has released its 2025 financial results and updates on its HBV treatment strategies, showcasing advancements in drug development and discovery.

Brii Biosciences Reports Major Developments and 2025 Financial Results #USA #Durham #Brii_Biosciences #HBV_Treatment #biotech_company

SCG Cell Therapy Unveils Groundbreaking Clinical Data for SCG101 in Hepatocellular Carcinoma Treatment SCG Cell Therapy introduces significant clinical findings on SCG101, a novel TCR T cell therapy for HBV-related hepatocellular carcinoma (HCC) at EASL Congress 2025.

SCG Cell Therapy Unveils Groundbreaking Clinical Data for SCG101 in Hepatocellular Carcinoma Treatment #Singapore #SCG101 #SCG_Cell_Therapy #HBV_Treatment

Brii Biosciences Shares Strategic Insights and Full-Year 2024 Results Explore Brii Biosciences' impactful updates on its HBV treatment strategies and the financial outcomes for the year 2024, including significant clinical advancements.

Brii Biosciences Shares Strategic Insights and Full-Year 2024 Results #USA #Durham #BRII-179 #Brii_Biosciences #HBV_Treatment